Compare LGND & FSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGND | FSK |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.0B |
| IPO Year | 1997 | 2008 |
| Metric | LGND | FSK |
|---|---|---|
| Price | $306.50 | $11.12 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 8 |
| Target Price | ★ $256.29 | $13.19 |
| AVG Volume (30 Days) | 172.3K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 18.82% |
| EPS Growth | ★ 2886.36 | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $141,102,000.00 | N/A |
| Revenue This Year | $1.25 | N/A |
| Revenue Next Year | $19.41 | N/A |
| P/E Ratio | $192.70 | ★ N/A |
| Revenue Growth | ★ 29.48 | N/A |
| 52 Week Low | $175.89 | $9.72 |
| 52 Week High | $326.63 | $16.31 |
| Indicator | LGND | FSK |
|---|---|---|
| Relative Strength Index (RSI) | 62.46 | 36.78 |
| Support Level | $286.99 | $10.41 |
| Resistance Level | $322.06 | $11.22 |
| Average True Range (ATR) | 9.45 | 0.24 |
| MACD | 3.06 | -0.09 |
| Stochastic Oscillator | 77.12 | 28.08 |
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.